Business
Block Listing Return
Oxford Biomedica PLC has reported on its employee share schemes for the period of July 1, 2025, to December 31, 2025. Under the 2015 Employee Share Option Scheme, 13,800 securities were issued, leaving a balance of 267,036 unallotted securities. The 2015 and 2024 Long Term Incentive Plan saw 362,154 securities issued, resulting in 628,075 remaining unallotted. For the 2015 and 2024 Deferred Bonus Plan, 128,536 securities were issued, with 393,913 unallotted. Finally, the Sharesave Scheme had 190,364 securities issued, leaving 148,676 unallotted. Disclaimer*
About this update from Oxford Biomedica Plc
Name of applicant: OXFORD BIOMEDICA PLC Name of scheme: 2015 Employee Share Option Scheme Period of return: From: 1 July 2025 To: 31 December 2025 Balance of unallotted securities under scheme(s) from previous return: 280,836 Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 13,800 Equals: Balance under scheme(s) not yet issued/allotted at end of period: 267,036 Name of applicant: OXFORD BIOMEDICA PLC Name of scheme: 2015 and 2024 Long Term Incentive Plan Period of return: From: 1 July 2025 To: 31 December 2025 Balance of unallotted securities under scheme(s) from previous return: 990,229 Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 362,154 Equals: Balance under scheme(s) not yet issued/allotted at end of period: 628,075 Name of applicant: OXFORD BIOMEDICA PLC Name of scheme: 2015 and 2024 Deferred Bonus Plan Period of return: From: 1 July 2025 To: 31 December 2025 Balance of unallotted securities under scheme(s) from previous return: 522,449 Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 128,536 Equals: Balance under scheme(s) not yet issued/allotted at end of period: 393,913 Name of applicant: OXFORD BIOMEDICA PLC Name of scheme: Sharesave Scheme Period of return: From: 1 July 2025 To: 31 December 2025 Balance of unallotted securities under scheme(s) from previous return: 339,040 Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 190,364 Equals: Balance under scheme(s) not yet issued/allotted at end of period: 148,676 48 Name of contact: Natalie Walter, Chief Legal Officer and Group Company Secretary Telephone number of contact: 01865 783000 -Ends- Enquiries: OXB: Natalie Walter, Chief Legal Officer and Group Company Secretary - T : +44 (0) 1865 783 000 / E: [email protected] About OXB OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechno logy companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities range from early - stage development to commercialisation. The se capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. OXB offers a vast number of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the Tetra V ecta™ system), a dual - plasmid system for AAV production, suspension and perfusion process using process enhancers and st able producer and packaging cell lines. OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France , Bedford MA, and Durham NC, US. Learn more at www.oxb.com and follow us on LinkedIn and YouTube.
View stock analysis, news, and events for Oxford Biomedica Plc